FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245099670> ?p ?o ?g. }

• W4245099670 abstract "Acute kidney injury (AKI) is a major comorbidity in hospitalised patients. Patients with severe AKI require continuous renal replacement therapy (CRRT) when they are haemodynamically unstable. CRRT is prescribed assuming it is delivered over 24 hours. However, it is interrupted when the extracorporeal circuits clot and the replacement is required. The interruption may impair the solute clearance as it causes under dosing of CRRT. To prevent the circuit clotting, anticoagulation drugs are frequently used.To assess the benefits and harms of pharmacological interventions for preventing clotting in the extracorporeal circuits during CRRT.We searched the Cochrane Kidney and Transplant Register of Studies up to 12 September 2019 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.We selected randomised controlled trials (RCTs or cluster RCTs) and quasi-RCTs of pharmacological interventions to prevent clotting of extracorporeal circuits during CRRT.Data were abstracted and assessed independently by two authors. Dichotomous outcomes were calculated as risk ratio (RR) with 95% confidence intervals (CI). The primary review outcomes were major bleeding, successful prevention of clotting (no need of circuit change in the first 24 hours for any reason), and death. Evidence certainty was determined using the Grading of Recommendation Assessment, Development, and Evaluation (GRADE) approach.A total of 34 completed studies (1960 participants) were included in this review. We identified seven ongoing studies which we plan to assess in a future update of this review. No included studies were free from risk of bias. We rated 30 studies for performance bias and detection bias as high risk of bias. We rated 18 studies for random sequence generation, six studies for the allocation concealment, three studies for performance bias, three studies for detection bias, nine studies for attrition bias, 14 studies for selective reporting and nine studies for the other potential source of bias, as having low risk of bias. We identified eight studies (581 participants) that compared citrate with unfractionated heparin (UFH). Compared to UFH, citrate probably reduces major bleeding (RR 0.22, 95% CI 0.08 to 0.62; moderate certainty evidence). Citrate may have little or no effect on death at 28 days (RR 1.06, 95% CI 0.86 to 1.30, moderate certainty evidence), while citrate versus UFH may have little or no effect on successful prevention of clotting (RR 1.01, 95% CI 0.77 to 1.32; moderate certainty evidence). Citrate versus UFH may reduce the number of participants who drop out of treatment due to adverse events (RR 0.47, 95% CI 0.15 to 1.49; low certainty evidence). Compared to UFH, citrate may make little or no difference to the recovery of kidney function (RR 0.95, 95% CI 0.66 to 1.36; low certainty evidence). Compared to UFH, citrate may reduce thrombocytopenia (RR 0.39, 95% CI 0.14 to 1.03; low certainty evidence). It was uncertain whether citrate reduces a cost to health care services because of inadequate data. For low molecular weight heparin (LMWH) versus UFH, six studies (250 participants) were identified. Compared to LMWH, UFH may reduce major bleeding (0.58, 95% CI 0.13 to 2.58; low certainty evidence). It is uncertain whether UFH versus LMWH reduces death at 28 days or leads to successful prevention of clotting. Compared to LMWH, UFH may reduce the number of patient dropouts from adverse events (RR 0.29, 95% CI 0.02 to 3.53; low certainty evidence). It was uncertain whether UFH versus LMWH leads to the recovery of kidney function because no included studies reported this outcome. It was uncertain whether UFH versus LMWH leads to thrombocytopenia. It was uncertain whether UFH reduces a cost to health care services because of inadequate data. For the comparison of UFH to no anticoagulation, one study (10 participants) was identified. It is uncertain whether UFH compare to no anticoagulation leads to more major bleeding. It is uncertain whether UFH improves successful prevention of clotting in the first 24 hours, death at 28 days, the number of patient dropouts due to adverse events, recovery of kidney function, thrombocytopenia, or cost to health care services because no study reported these outcomes. For the comparison of citrate to no anticoagulation, no completed study was identified.Currently, available evidence does not support the overall superiority of any anticoagulant to another. Compared to UFH, citrate probably reduces major bleeding and probably has little or no effect on preventing clotting or death at 28 days. For other pharmacological anticoagulation methods, there is no available data showing overall superiority to citrate or no pharmacological anticoagulation. Further studies are needed to identify patient populations in which CRRT should commence with no pharmacological anticoagulation or with citrate." @default.
• W4245099670 created "2022-05-12" @default.
• W4245099670 creator A5000674213 @default.
• W4245099670 creator A5017115362 @default.
• W4245099670 creator A5039593848 @default.
• W4245099670 creator A5081912842 @default.
• W4245099670 creator A5083220097 @default.
• W4245099670 creator A5087414648 @default.
• W4245099670 creator A5091508879 @default.
• W4245099670 date "2020-03-12" @default.
• W4245099670 modified "2023-09-24" @default.
• W4245099670 title "Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy" @default.
• W4245099670 cites W147166911 @default.
• W4245099670 cites W1486294261 @default.
• W4245099670 cites W1531106656 @default.
• W4245099670 cites W1575455824 @default.
• W4245099670 cites W1582176913 @default.
• W4245099670 cites W173229655 @default.
• W4245099670 cites W1835524577 @default.
• W4245099670 cites W1853945267 @default.
• W4245099670 cites W1970935602 @default.
• W4245099670 cites W1972649334 @default.
• W4245099670 cites W1973714169 @default.
• W4245099670 cites W1977944302 @default.
• W4245099670 cites W1989567087 @default.
• W4245099670 cites W1992465451 @default.
• W4245099670 cites W2016934130 @default.
• W4245099670 cites W2018285429 @default.
• W4245099670 cites W2019511213 @default.
• W4245099670 cites W2032028261 @default.
• W4245099670 cites W2039402594 @default.
• W4245099670 cites W2041510694 @default.
• W4245099670 cites W2045603627 @default.
• W4245099670 cites W2047915156 @default.
• W4245099670 cites W2052466310 @default.
• W4245099670 cites W2057049224 @default.
• W4245099670 cites W2061948194 @default.
• W4245099670 cites W2062586787 @default.
• W4245099670 cites W2063729575 @default.
• W4245099670 cites W2078335793 @default.
• W4245099670 cites W2089267111 @default.
• W4245099670 cites W2091259644 @default.
• W4245099670 cites W2099865965 @default.
• W4245099670 cites W2100972869 @default.
• W4245099670 cites W2103023439 @default.
• W4245099670 cites W2104675861 @default.
• W4245099670 cites W2106483380 @default.
• W4245099670 cites W2112425320 @default.
• W4245099670 cites W2112492495 @default.
• W4245099670 cites W2115262523 @default.
• W4245099670 cites W2115632174 @default.
• W4245099670 cites W2116900376 @default.
• W4245099670 cites W2117958746 @default.
• W4245099670 cites W2118575683 @default.
• W4245099670 cites W2119483013 @default.
• W4245099670 cites W2125435699 @default.
• W4245099670 cites W2126189520 @default.
• W4245099670 cites W2126584900 @default.
• W4245099670 cites W2128125215 @default.
• W4245099670 cites W2130502422 @default.
• W4245099670 cites W2138575779 @default.
• W4245099670 cites W2139197357 @default.
• W4245099670 cites W2141202722 @default.
• W4245099670 cites W2141559993 @default.
• W4245099670 cites W2143195851 @default.
• W4245099670 cites W2149269520 @default.
• W4245099670 cites W2150433066 @default.
• W4245099670 cites W2152587962 @default.
• W4245099670 cites W2157358562 @default.
• W4245099670 cites W2160093627 @default.
• W4245099670 cites W2165010366 @default.
• W4245099670 cites W2171029622 @default.
• W4245099670 cites W2171478303 @default.
• W4245099670 cites W2182428690 @default.
• W4245099670 cites W2246338608 @default.
• W4245099670 cites W2329722222 @default.
• W4245099670 cites W2352105328 @default.
• W4245099670 cites W2400780832 @default.
• W4245099670 cites W2407690400 @default.
• W4245099670 cites W2413171623 @default.
• W4245099670 cites W2462705496 @default.
• W4245099670 cites W2582602949 @default.
• W4245099670 cites W2588681363 @default.
• W4245099670 cites W2776609926 @default.
• W4245099670 cites W2777477762 @default.
• W4245099670 cites W2895319410 @default.
• W4245099670 cites W2916841405 @default.
• W4245099670 cites W2952762910 @default.
• W4245099670 cites W4230366664 @default.
• W4245099670 cites W4237330031 @default.
• W4245099670 cites W4243645202 @default.
• W4245099670 cites W4244149070 @default.
• W4245099670 cites W4248055999 @default.
• W4245099670 doi "https://doi.org/10.1002/14651858.cd012467.pub2" @default.
• W4245099670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32164041" @default.
• W4245099670 hasPublicationYear "2020" @default.
• W4245099670 type Work @default.
• W4245099670 citedByCount "8" @default.
• W4245099670 countsByYear W42450996702020 @default.
• W4245099670 countsByYear W42450996702021 @default.

• next